Medicine reconciliation | Medibuddy
17th May 2025

Medicine reconciliation

Polypharmacy is the concurrent use of 4 or more regular medications in an individual. It can be appropriate in many instances in patients with complex comorbidities, but clinicians must be able to recognise inappropriate polypharmacy that is much more common in older people.

Problems & consequences of inappropriate polypharmacy include:

  • Adverse drug interactions
  • Pill burden
    • Poor compliance
    • Confusion as to what, when and how to take drugs
    • Sense of lack of control over own healthcare
  • Increased hospital admission and healthcare cost

Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) are evidence-based guidelines used in the United Kingdom aimed to prevent inappropriate prescribing and omission of essential medicines (seeTable 3). Utilising STOPP/START criteria has reduced the number of adverse drug events and medical costs, whilst improving activities of daily living.

Medication Circumstances to review Potential adverse effect
Anticholinergics For treating EPS caused by antipsychotics

Patients with dementia, glaucoma, chronic constipation, prostatism

Anticholinergic toxicity

Exacerbation of respective conditions

Cardiovascular
Aspirin Concurrent anti-coagulation drugs

Bleeding disorder

Peptic ulcer disease (PUD)

Bleeding
Beta blockers Concurrent non-dihydropyridine calcium channel blockers (CCB)

Patient with diabetes mellitus and frequent hypoglycaemic episodes

Patient with asthma (especially non-cardioselective beta blockers)

Symptomatic heart block

Masking hypoglycaemic symptoms

Bronchospasm

Calcium channel blocker (CCB) Heart failure (especially non-dihydropyridine CCB)

Chronic constipation

Side effect of ankle oedema

Exacerbating conditions

Clopidogrel, Dipyridamole Concurrent bleeding disorder Bleeding
Digoxin Dose >125μg + impaired renal function (eGFR <50 ml/min) Toxicity (e.g. nausea, diarrhoea, arrhythmia)
Diuretics Loop diuretics + heart failure

Thiazides + history of gout

No mortality benefit

Exacerbating gout

Statins Prognosis of <6 months without acute ischaemic vascular condition (e.g. Acute coronary syndrome, Cerebrovascular syndrome)

Symptoms of muscle weakness or pain

No benefit to mortality whilst increasing polypharmacy

Risk of myopathy and rhabdomyolysis

Vasodilator (e.g. Hydralazine, Minoxidil, Sildenafil) Postural hypotension Syncope and falls
Warfarin Hepatic impairment with impaired clotting and raised INR Bleeding
Psychotropics
Antipsychotics For >1 month

Recurrent falls

Managing behavioural and psychological symptoms of dementia

Exacerbating confusion, EPS (especially in Parkinson’s disease), falls, gait dyspraxia
Benzodiazepines For >1 month

Recurrent falls

Prolonged sedation, confusion, impaired balance, falls
Domperidone Underlying cardiac condition

Co-prescribed medication that lengthens QT interval or potent P450 inhibitor

Risk of cardiac arrhythmia secondary to long QT interval
Dopamine antagonist (e.g. Prochlorperazine, Chlorpromazine, Metoclopramide) Patients with Epilepsy

Patients with Parkinson’s disease

Lower seizure threshold

Exacerbating condition

First generation antihistamines (e.g., Chlorpheniramine,

Promethazine,

Cyclizine)

Used for >1 week

Recurrent falls

Sedation, falls, anticholinergic side effects
Selective serotonin receptor inhibitor (SSRI) Serum sodium <130 mmol/L within past 2 months

Risk of QT prolongation (especially Citalopram and Escitalopram)

Worsening hyponatraemia

Cardiac arrhythmia secondary to long QT interval

Tricyclic antidepressants (TCA) Cardiac conduction abnormality

Concurrent opioids or CCB

Prostatism or history of urinary retention

Risk of arrhythmia

Risk of severe constipation

Risk of urinary retention

Respiratory
Ipratropium Patient with glaucoma Exacerbating glaucoma
Gastrointestinal
Anti-diarrhoeal (e.g. Loperamide) For diarrhoea of unknown cause Delayed diagnosis and recovery of gastroenteritis, toxic megacolon in inflammatory bowel disease (IBD), exacerbate constipation, overflow diarrhoea
Antiemetics (dopamine antagonists) [same as anticholinergics]
Bisphosphonates Unable to sit upright

Swallowing difficulty

Severe upper GI disorder (e.g. oesophagitis)
Laxatives (stimulant e.g. Bisacodyl, Senna, Metoclopramide) Patient with intestinal obstruction Bowel perforation
Proton pump inhibitor (PPI) High dose for >8 weeks

Concurrent Clopidogrel

Increased risk of Clostridium difficile infection

Reduce antiplatelet effect

Endocrine
Corticosteroids (systemic) Maintenance therapy in moderate-severe chronic obstructive pulmonary disease (COPD)

>3 months monotherapy for rheumatoid arthritis or osteoarthritis

Unnecessary exposure to long-term side effect of medication
Metformin Renal impairment:

Review dose if eGFR <45 ml/min

Avoid if eGFR <30ml/min

Lactic acidosis
Oestrogen (systemic) History of breast cancer or venous thromboembolism (VTE)

Monotherapy in individuals with uterus

Recurrence of conditions

Endometrial cancer

Pioglitazone Heart failure

All elderly patients

Exacerbating heart failure

Fracture and bladder cancer

Sulfonylurea Patient with type 2 diabetes mellitus Prolonged hypoglycaemia
Urogenital
Bladder antispasmodics Patients with dementia, glaucoma, chronic constipation, prostatism Exacerbating conditions
Alpha blockers Male urinary incontinence >1x/day Urinary frequency and worsening of incontinence
Analgesia
NSAID History of PUD or gastrointestinal (GI) bleed without gastroprotection

Mod-severe hypertension (>160/100), heart failure, chronic kidney disease

Concurrent Warfarin, SSRI, corticosteroids (>3 months monotherapy)

≥65yo + eGFR <60ml/min or heart failure

PUD relapse

Exacerbating condition

GI bleeding

Deterioration of renal function

Opioids Long term use of strong opiates as first line for mild-moderate pain

>2 weeks in chronic constipation without concurrent laxatives

Long term in dementia + not palliative + not for specific pain syndrome

Recurrent falls

WHO analgesic ladder not observed

Severe constipation

Exacerbating cognitive impairment

Drowsiness, falls, vertigo

Table 3. Summary of STOPP guidance

As a general principle, any duplication of drug class should be reviewed and preferably removed to reduce side effects and polypharmacy. Avoid concurrent use of several sedative medications due to increased risk of overdose and respiratory depression.

Despite general clinical consensus regarding stopping anticoagulants in recurrent falls, there has not been any evidence supporting this. Starting or stopping anticoagulants for specific indications (e.g., atrial fibrillation) should be based on a balance of risks between risk of thrombotic event and bleeding risks. Scoring systems should be utilised to make an informed decision (i.e. CHA2DS2-VASc score for risk of cerebrovascular event in atrial fibrillation, ORBIT and HASBLED for risk of bleeding).

Medication Conditions
Safer and more effective alternatives available
Diuretics (monotherapy) Hypertension

Dependent/gravitational ankle oedema + no signs of heart failure

NSAIDs >3 months in mild osteoarthritis

Gout

Theophylline (monotherapy) COPD
No proven benefit
Aspirin No arterio-occlusive disease
Dipyridamole (monotherapy) Stroke
Warfarin >6 months for first DVT

>12 months for first PE

Table 4. Summary of START guidance

Warfarin is an important medication to take note of when starting or stopping medications as many drugs can affect its anticoagulant effect, mainly by potentiating or inhibiting the cytochrome P450 system responsible for metabolising warfarin. When starting any drugs that can alter warfarin metabolism (Table 5), monitor international normalised ratio (INR) closely and modify warfarin dose if necessary. Several antibiotic classes and antiepileptic drugs (AED) are the most common causes. Patients will also need to be reminded that some food items should be avoided to maintain a stable Warfarin level. Patients with liver disease are likely to have impaired Warfarin metabolism, thus a lower dose may be required to achieve target INR.

Mechanism of effect Medication
Decrease warfarin effect
Cytochrome P450 inducer Alcohol (chronic intake)
Barbiturates (e.g., Phenobarbitone, Thiopentone, Chlormethiazole)
Carbamazepine
Griseofulvin
Phenytoin
Rifampicin
Smoking
St John’s Wort
Sulfonylureas (e.g., Glibenclamide, Gliclazide, Glyclopyramide)
Impair gastrointestinal uptake of warfarin PPI
Cholestyramine
Replenishment of vitamin K Food rich in vitamin K (e.g. broccoli, kale, spinach)
Increase warfarin effect
Cytochrome P450 inhibitor Alcohol (acute)
Allopurinol
Amiodarone
Azole antifungals (e.g., Ketoconazole, Fluconazole)
Chloramphenicol
Cimetidine
Cranberry juice
Disulfiram
Quinolone antibiotics (e.g. Ciprofloxacin, Norfloxacin, Ofloxacin, Nalidixic acid)
Grapefruit juice
Isoniazid
Macrolide antibiotics (e.g., Clarithromycin, Erythromycin)
Metronidazole
Omeprazole
Ritonavir
SSRI (e.g., Fluoxetine, Paroxetine, Sertraline, Citalopram)
Sulphonamide antibiotics
Valproate
Verapamil
Displace warfarin from binding to plasma albumin NSAIDs

Table 5. Drugs that alter warfarin anticoagulant effect

Below is a simple guide as to how to reconcile and review medications for elderly patients:

  • Remove medications that are not indicated by their current conditions
  • Limit the range of drug class to reduce possible drug-drug interactions
  • Start with lower dosage within the effective range, and titrate according to symptoms slowly if necessary
  • Simplify regimen and keep the number of doses per day to a minimum
  • Review regularly, especially at each admission and change in condition
Mobile app screenshots

Take your subscriptions with you

Our mobile app allows you to access your interview and exam question banks wherever you are.